C. Aversa

Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.

N. Vasudev, S. Tolan, R. Conroy, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients

S. Bonin, E. Roggero, G. Stanta, 2016, Radiology and oncology.

Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients

S. Bonin, N. Tsuchida, M. Castellone, 2018, Oncotarget.